TAIPEI, TAIWAN (UroToday.com) - Predisposition for stone formation is a combination of multiple factors, both genetic and environmental. The team at the University of Wisconsin sought to understand the role family history (FH) plays in stone formation, metabolic abnormalities, and risk of stone recurrence. They looked at differences between first, second, and third degree family history, an aspect of the study that makes it unique.

wceDr. Necole Streeper, in her presentation, emphasized that it is important to query family history in all patients in order to set appropriate goals for treatment.

She went on to demonstrate that metabolic abnormalities, most commonly hyperoxaluria, were more prevalent in those with adult onset stone disease, and those with greater than one degree of FH. Interestingly, those patients with a strong FH (> 1 degree) had a significantly higher incidence of stone recurrence. Family history is clearly an important part of the workup of metabolic stone disease.

Presented by Necole M. Streeper, Kristina L. Penniston, and Stephen Y. Nakada at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan

University of Wisconsin School of Medicine and Public Health, Madison, WI USA

Written by Adam Kaplan, MD, chief resident, Department of Urology, School of Medicine, University of California-Irvine, and medical writer for UroToday.com

 

Calendar
Upcoming urology industry events
April 27-29, 2018 / European Society for Medical Oncology Update for Practising Oncologists
European Society for Medical Oncology Update for Practising Oncologists
May 14, 2018 / InterContinental Mark Hopkins Hotel
SITC Cancer Immune Responsiveness Workshop
May 16-17, 2018 / InterContinental Mark Hopkins Hotel
SITC Immuno-Oncology Biomarkers: State of the Art Workshop
May 17, 2018 / Moscone Convention Center North/South, San Francisco, CA
SAU 2018 Annual Meeting at the AUA
Journals
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor